Inhalable nanoparticles to treat lung cancer
- what is different to conventional therapies?
- what is different to conventional therapies?
报告人：Raimar Löebenberg
报告时间：2013年10月23日上午9:30-10:30
报告地点：科技大厦1313
报告人简介
Dr. Löbenberg holds a BS in pharmacy from the Johannes Gutenberg-University in Mainz, Germany. He received his PhD in pharmaceutics from the Johann Wolfgang Goethe-University in Frankfurt in 1996. He joined the University of Alberta in 2000 and is Professor in Pharmaceutics at the Faculty of Pharmacy and Pharmaceutical Sciences. His research interests are in Biopharmaceutics to predict the oral performance of drugs and botanical and inhalable nanoparticles to treat lung cancer.
He is founder and director of the Drug Development and Innovation Centre at the University of Alberta: www.DDIC.ca , which is the only Health Canada licensed university based manufacturing facility in Canada.
He is Vice Chair of the Specialty Committee of Traditional Chinese Medicine in Pharmaceutics of the World Foundation of Chinese Medicine Science.